Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.78
FLML's Cash to Debt is ranked higher than
54% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. FLML: 0.78 )
FLML' s 10-Year Cash to Debt Range
Min: 0.08   Max: 49.99
Current: 0.78

0.08
49.99
Equity to Asset 0.14
FLML's Equity to Asset is ranked higher than
51% of the 1113 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. FLML: 0.14 )
FLML' s 10-Year Equity to Asset Range
Min: -0.08   Max: 0.8
Current: 0.14

-0.08
0.8
F-Score: 4
Z-Score: -0.98
M-Score: -3.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -635.24
FLML's Operating margin (%) is ranked higher than
60% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -79.37 vs. FLML: -635.24 )
FLML' s 10-Year Operating margin (%) Range
Min: -1285   Max: 15.94
Current: -635.24

-1285
15.94
Net-margin (%) -574.66
FLML's Net-margin (%) is ranked higher than
60% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. FLML: -574.66 )
FLML' s 10-Year Net-margin (%) Range
Min: -1027.16   Max: 22.56
Current: -574.66

-1027.16
22.56
ROE (%) -221.78
FLML's ROE (%) is ranked higher than
50% of the 1371 Companies
in the Global Biotechnology industry.

( Industry Median: -28.22 vs. FLML: -221.78 )
FLML' s 10-Year ROE (%) Range
Min: -1103.89   Max: 30.36
Current: -221.78

-1103.89
30.36
ROA (%) -52.33
FLML's ROA (%) is ranked higher than
60% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. FLML: -52.33 )
FLML' s 10-Year ROA (%) Range
Min: -58.46   Max: 14.58
Current: -52.33

-58.46
14.58
ROC (Joel Greenblatt) (%) -627.19
FLML's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. FLML: -627.19 )
FLML' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2003.78   Max: 76.01
Current: -627.19

-2003.78
76.01
Revenue Growth (3Y)(%) -32.30
FLML's Revenue Growth (3Y)(%) is ranked higher than
63% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. FLML: -32.30 )
FLML' s 10-Year Revenue Growth (3Y)(%) Range
Min: -52.8   Max: 42.6
Current: -32.3

-52.8
42.6
EBITDA Growth (3Y)(%) 106.50
FLML's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. FLML: 106.50 )
FLML' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -50.2   Max: 126.3
Current: 106.5

-50.2
126.3
EPS Growth (3Y)(%) 89.50
FLML's EPS Growth (3Y)(%) is ranked higher than
99% of the 824 Companies
in the Global Biotechnology industry.

( Industry Median: -4.80 vs. FLML: 89.50 )
FLML' s 10-Year EPS Growth (3Y)(%) Range
Min: -38.2   Max: 89.5
Current: 89.5

-38.2
89.5
» FLML's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

FLML Guru Trades in

FLML Guru Trades in

FLML Guru Trades in

Q1 2015

FLML Guru Trades in Q1 2015

Steven Cohen 355,800 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with FLML

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 16.10
FLML's Forward P/E is ranked higher than
96% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. FLML: 16.10 )
N/A
P/B 28.58
FLML's P/B is ranked lower than
54% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. FLML: 28.58 )
FLML' s 10-Year P/B Range
Min: 1.83   Max: 30.47
Current: 28.58

1.83
30.47
P/S 37.70
FLML's P/S is ranked higher than
61% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 40.71 vs. FLML: 37.70 )
FLML' s 10-Year P/S Range
Min: 2.3   Max: 64.35
Current: 37.7

2.3
64.35
EV-to-EBIT -7.86
FLML's EV-to-EBIT is ranked lower than
55% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. FLML: -7.86 )
FLML' s 10-Year EV-to-EBIT Range
Min: -811.9   Max: 125.4
Current: -7.86

-811.9
125.4
Current Ratio 1.59
FLML's Current Ratio is ranked higher than
56% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.49 vs. FLML: 1.59 )
FLML' s 10-Year Current Ratio Range
Min: 0.83   Max: 6.76
Current: 1.59

0.83
6.76
Quick Ratio 1.49
FLML's Quick Ratio is ranked higher than
58% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. FLML: 1.49 )
FLML' s 10-Year Quick Ratio Range
Min: 0.77   Max: 6.7
Current: 1.49

0.77
6.7
Days Inventory 567.69
FLML's Days Inventory is ranked higher than
77% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. FLML: 567.69 )
FLML' s 10-Year Days Inventory Range
Min: 17.66   Max: 1276.2
Current: 567.69

17.66
1276.2
Days Sales Outstanding 41.48
FLML's Days Sales Outstanding is ranked higher than
90% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 141.98 vs. FLML: 41.48 )
FLML' s 10-Year Days Sales Outstanding Range
Min: 39.95   Max: 541.87
Current: 41.48

39.95
541.87

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 6.01
FLML's Price/Median PS Value is ranked higher than
62% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. FLML: 6.01 )
FLML' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 7.52
Current: 6.01

0.38
7.52
Earnings Yield (Greenblatt) -12.70
FLML's Earnings Yield (Greenblatt) is ranked higher than
57% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. FLML: -12.70 )
FLML' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 3.7
Current: -12.7

0.8
3.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:FL3.Germany,
Flamel Technologies was incorporated as a Societe Anonyme or SA, a form of corporation under the laws of the Republic of France in August 1990 as Flamel Technologies S.A. The Company is a specialty pharmaceutical company with a history in drug delivery, working on the development of safer and more efficacious formulations. The acquisition of Éclat on March 13, 2012 has created a more vertically integrated company, benefiting from greater development and commercial expertise and more near-term and mid-term potential value creating catalysts. Since its acquisition of Eclat, Flamel is now engaged in not only on the development and licensing of versatile, proprietary drug delivery platforms but also on the development of novel, high-value products based on those delivery platforms. Bloxiverz, the Company first NDA approval from the portfolio of Eclat products acquired in March 2012. Bloxiverz's NDA was filed in August 2012 and approved by the FDA on May 2013. The launch of Bloxiverz commenced in July 2013. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Bloxiverz is the first and only FDA-approved version of neostigmine methylsulfate, even though other versions of neostigmine have been on the market as unapproved, grandfathered products under the Food, Drug and Cosmetic Act of 1938. Coreg CR, the lead product using its Micropump drug delivery platform. Coreg CR is an extended-release formulation once-a-day of Coreg a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors. The Company faces competition from Actavis, Alkermes, BioAlliance Pharma, Depomed, Ethypharm, Octoplus, Veloxis Pharmaceuticals, Nektar Therapeutics. The Company owns and develops drug delivery platforms that are able to tackle key challenges in the formulation, in various dosage forms of a broad range of drugs novel, already-marketed, or off-patent that includes Micropump. During the 2013 the Company has 395 patents in total. The design, testing, manufacturing and marketing of certain new or substantially modified drugs, biological products or medical devices must be approved, cleared or certified by regulatory agencies, regulatory authorities and Notified Bodies under applicable laws and regulations, the requirements of which may vary from country to country.
» More Articles for FLML

Headlines

Articles On GuruFocus.com
Flamel Technologies Announces Price Change for Bloxiverz Jan 15 2015 
Flamel Technologies Update to Shareholders on Neostigmine Methylsulfate Jan 14 2015 
Flamel Technologies Announces Positive Results of a Second Clinical Trial With Micropump(R) Sodium O Dec 19 2014 
Flamel Technologies Transfers Intangible Property to Irish-Based Subsidiary in Global Reorganization Dec 16 2014 
Flamel Technologies to Be Included in NASDAQ Biotech Index Dec 15 2014 
Flamel Technologies Sells Development and Manufacturing Facility in Pessac, France to Recipharm AB Nov 28 2014 
Flamel Technologies to Report Third Quarter of Fiscal Year 2014 Results Oct 21 2014 
Flamel Technologies Announces Positive Results of First-in-Man Clinical Trial With LiquiTime(R) Ibup Oct 15 2014 
Flamel Technologies Announces Second Quarter 2009 Results; Multiple New Projects; Cash Increases fro Aug 05 2009 
Flamel Technologies Announces Projected Release Date of Second Quarter Results; Conference Call Jul 28 2009 

More From Other Websites
Why Flamel Technologies (FLML) Could Be Positioned for a Surge? - Tale of the Tape May 26 2015
Flamel Technologies to present at Jefferies 2015 Healthcare Conference May 22 2015
Flamel Technologies Announces First Quarter Results of Fiscal Year 2015 May 22 2015
Flamel Technologies to Present at Jefferies 2015 Healthcare Conference May 22 2015
Flamel Technologies Is Fired Up May 19 2015
Heron Therapeutics (HRTX) Worth Watching: Stock Up 11.4% - Tale of the Tape May 18 2015
Onconova Therapeutics (ONTX) Looks Good: Stock Up 5.8% - Tale of the Tape May 18 2015
Auris Medical Holding AG (EARS) Looks Good: Stock Up 6.1% - Tale of the Tape May 15 2015
Flamel Technologies Announces First Quarter Results of Fiscal Year 2015 May 15 2015
Q1 2015 Flamel Technologies SA Earnings Release - Before Market Open May 15 2015
BSQUARE, OraSure Technologies, Avon Products Lead Thursday's After-Hours Movers May 14 2015
Tokai Pharmaceuticals (TKAI) Jumps: Stock Moves Up 6.1% - Tale of the Tape May 14 2015
Can the Rally in Flamel Technologies (FLML) Shares Continue? - Tale of the Tape May 13 2015
Spectrum Pharmaceuticals (SPPI) in Focus: Stock Up 10.1% - Tale of the Tape May 13 2015
Apple Inc. (AAPL), Flamel Technologies S.A. (FLML), and Johnson & Johnson (JNJ): Bailard’s Top Q2... May 12 2015
Calithera Biosciences Crumbles: CALA Falls 7.6% in Session - Tale of the Tape May 12 2015
Calithera Biosciences (CALA) in Focus: Stock Rises 45.7% - Tale of the Tape May 11 2015
Flamel Technologies (FLML) in Focus: Stock Rises 10.6% - Tale of the Tape May 11 2015
Flamel Technologies to report first quarter of fiscal year 2015 results May 07 2015
Flamel Technologies to Report First Quarter of Fiscal Year 2015 Results May 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK